Aviva PLC Buys 29,992 Shares of STERIS plc (NYSE:STE)

Aviva PLC boosted its stake in STERIS plc (NYSE:STEGet Rating) by 97.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,926 shares of the medical equipment provider’s stock after acquiring an additional 29,992 shares during the period. Aviva PLC owned 0.06% of STERIS worth $14,730,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in STE. UMB Bank N A MO bought a new stake in STERIS in the fourth quarter valued at $125,000. AlphaCrest Capital Management LLC lifted its position in STERIS by 27.6% during the fourth quarter. AlphaCrest Capital Management LLC now owns 6,753 shares of the medical equipment provider’s stock valued at $1,644,000 after buying an additional 1,460 shares during the period. HighTower Advisors LLC lifted its position in STERIS by 1.6% during the fourth quarter. HighTower Advisors LLC now owns 22,582 shares of the medical equipment provider’s stock valued at $5,488,000 after buying an additional 355 shares during the period. B. Riley Wealth Management Inc. purchased a new position in STERIS during the fourth quarter valued at $211,000. Finally, Glenview Trust Co lifted its position in STERIS by 16.5% during the fourth quarter. Glenview Trust Co now owns 1,839 shares of the medical equipment provider’s stock valued at $447,000 after buying an additional 260 shares during the period. Institutional investors own 92.04% of the company’s stock.

Wall Street Analysts Forecast Growth

STE has been the subject of several recent research reports. JMP Securities lowered their price objective on STERIS from $270.00 to $250.00 in a research report on Thursday, August 4th. Needham & Company LLC lowered their price objective on STERIS from $248.00 to $237.00 and set a “buy” rating for the company in a research report on Thursday, August 4th. KeyCorp lowered their price objective on STERIS from $256.00 to $240.00 and set an “overweight” rating for the company in a research report on Thursday, August 4th. StockNews.com raised STERIS from a “hold” rating to a “buy” rating in a research report on Thursday, August 11th. Finally, TheStreet raised STERIS from a “c+” rating to a “b” rating in a research report on Tuesday, August 2nd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $252.00.

Insider Buying and Selling

In related news, VP John Adam Zangerle sold 2,659 shares of STERIS stock in a transaction dated Wednesday, June 15th. The stock was sold at an average price of $205.31, for a total value of $545,919.29. Following the completion of the sale, the vice president now directly owns 27,936 shares in the company, valued at approximately $5,735,540.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.95% of the stock is owned by corporate insiders.

STERIS Price Performance

NYSE STE opened at $204.83 on Friday. STERIS plc has a one year low of $192.40 and a one year high of $255.93. The stock has a 50-day moving average of $209.86 and a 200 day moving average of $221.69. The company has a market capitalization of $20.49 billion, a price-to-earnings ratio of 54.91 and a beta of 0.75. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.35 and a current ratio of 2.03.

STERIS Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 23rd. Investors of record on Wednesday, September 7th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.92%. This is an increase from STERIS’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, September 6th. STERIS’s dividend payout ratio (DPR) is presently 50.40%.

STERIS Company Profile

(Get Rating)

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Read More

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.